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In their recently published commentary, Bradbury and colleagues [1] drew attention to the
possible negative interactions between helminth infection and COVID-19 severity in hel-
minth-endemic regions. Helminth infections are known to be powerful modulators of the
human immune response, and numerous studies now highlight the effects this may have on
human infectious, inflammatory, and metabolic diseases. We believe, however, that any inter-
action between pre-existing helminth infection and the subsequent severity of COVID-19
need not necessarily be a negative one, and theoretical and empirical evidence suggests that
helminths may indeed have a mitigating effect.
One of the clear predictors of severe COVID-19 that has emerged during the pandemic has
been the presence of obesity, metabolic syndrome, or type 2 diabetes mellitus (T2DM) in
patients contracting the virus. [2] These conditions are associated with the second week “cyto-
kine storm” phenomenon [3] that often results in the need for ventilatory support and
increased mortality, including in younger patients. These metabolic diseases are characterised
by an inflammatory milieu, with increased levels of proinflammatory cytokines, many of
which are also implicated in the severe form of COVID-19. Elevated levels of acute phase reac-
tants and proinflammatory cytokines including IFN-γ, IL-1β, IL-6, IL-12, IL-17, IL-18, IL-27,
and TNF have been shown to be predictors of clinical deterioration and the onset of severe dis-
ease. Lymphopaenia (and, in particular, a reduction in regulatory T cells [Treg] numbers) and
eosinopaenia are also closely associated with disease severity. [4]
Epidemiological studies over the past decade have consistently reported an inverse relation-
ship between a variety of chronic helminth infections and the presence of metabolic syndrome
and T2DM, particularly in transitional societies in which both conditions are prevalent. [5]
Recent reports have shown reduced levels of proinflammatory cytokines such as IL-1α, IL-1β,
IL-6, IL-12, IL-18, IL-23, IL-27, G-CSF, and GM-CSF in subjects with coexisting helminth
infection and T2DM and a partial reversal of this effect following treatment of the worm infec-
tion. [6] In addition, chronic helminth infections are associated with increased numbers of
Treg cells, M2 macrophages, and eosinophils. It is therefore feasible to propose that a reduced
capacity for the production of proinflammatory cytokines and increased numbers of regula-
tory immune cells due to the immunomodulatory effects of pre-existing helminth infection
could result in a reduced risk of severe COVID-19.
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Although the interaction between helminth infection and viral pneumonia is poorly
defined, there is some evidence that helminth infection may moderate the process of pulmo-
nary inflammation in viral infections. Some studies have suggested that helminth infection
may impair responses to viral immunization [7] and viral infection [8], but no clear clinical
evidence exists that it acts to worsen outcomes. [9] The increased levels of IL-4 and IL-10
(anti-inflammatory cytokines associated with chronic helminth infection) found in some stud-
ies [10] need not represent a virus induced pathological response but could instead reflect the
normal regulatory and tissue-repair response to inflammation.
Epidemiological studies of the prevalence of severe COVID-19 in societies in which hel-
minth infection is common would clearly be of great interest, but currently, no reliable data
exists. The pandemic has been most active in developed countries where helminth infection is
rare, and the data coming from less-developed societies may be difficult to interpret given the
early phase of the pandemic, the lack of extensive testing, unreliable information regarding
case fatality rates and cause of death, and their generally younger populations with lower prev-
alence of metabolic disease and obesity. The numbers currently emerging from the WHO do
not indicate a widespread increase in case fatality rates in the developing world, with the num-
ber of reported deaths being generally low. [11]
We believe that, as the understanding of the mechanisms of severe COVID-19 evolves,
there may be a case for exploring the possible effects of experimental helminth infection (EHI)
on COVID-19 severity in a study setting. This is particularly so should the mechanism of
severe disease rest principally in endothelial invasion and vascular injury secondary to
unchecked inflammatory responses, rather than ongoing viral replication. [12] Although the
outcomes of trials have been mixed [13], experimental inoculation with the hookworm Neca-
tor americanus has been established as both practical and safe for use in study settings and has
been successfully deployed in trials involving atopic and autoimmune disorders. [14] Impor-
tantly, no data exists studying the effect on metabolic outcomes, but one study is currently
underway examining the effect of EHI on individuals with obesity and metabolic syndrome.
[15] In the present crisis, a prospective study examining the effect of EHI on subsequent severe
COVID-19 could produce valuable insights into the immunology of this condition. Clearly,
the design of such a study would pose considerable ethical and practical challenges. Experi-
mental coronavirus infection would seem impossible, particularly given that the trial would
logically target those at most risk of severe disease. A case-matched cohort study conducted at
multiple locations around the world would require large numbers of subjects and would be
dependent on the unpredictable future course of the pandemic. Nevertheless, such a trial
could demonstrate a potential mitigation of severe disease in susceptible individuals and give
some evidence-based guidance on how to best manage the helminth elimination programs
currently operating in many countries as the pandemic unfolds over coming years.
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